Document is current

Article History

Received: 19 August 2025

Accepted: 20 November 2025

First Online: 7 January 2026

Declarations

:

: Philip Mease has received research support, consulting fees, and/or speaker bureau support from AbbVie, Acelyrin, Amgen, BMS, Century, Cullinan, Lilly, Inmagene, Johnson & Johnson, Moonlake Pharma, Novartis, Pfizer, Spyre, Sun, UCB, and Takeda. Xiaolan Ye, Christopher D Saffore, Bhumik Parikh, and Sandra Ciecinski are employees of AbbVie and may own stock or stock options. Taylor Blachley is an employee and stockholder of Thermo Fisher Scientific, Inc. This study was a collaborative effort between PPD clinical research business of Thermo Fisher and AbbVie with financial support provided by AbbVie. Melissa Eliot and Nicole Middaugh are employees of Thermo Fisher. CorEvitas Clinical Registries are supported through contracted subscriptions with multiple pharmaceutical companies. This study was a collaborative effort between PPD clinical research business of Thermo Fisher and AbbVie with financial support provided by AbbVie. Alexis Ogdie is a consultant for AbbVie, Amgen, BMS, Celgene, the PPD clinical research business of Thermo Fisher, Gilead, GSK, Janssen, Lilly, Novartis, Takeda, TREG, Pfizer, and UCB; and received grants and/or research support from AbbVie (to University of Pennsylvania), Amgen (to Forward), BMS (to Forward), Forward/National Databank for Rheumatic Diseases, Janssen (to University of Pennsylvania), NIH/NIAMS, Novartis (to University of Pennsylvania), and Pfizer (to University of Pennsylvania).

: This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human patients with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (NEIRB; no. 120160610). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to the PPD™ clinical research business of Thermo Fisher Scientific (Waltham, MA, USA) before the site’s participation and initiation of any study procedures. All patients enrolled in the PPD™ CorEvitas™ PsA/SpA Registry were required to provide written informed consent and authorization before participating in the study.